Leadership
Rodney S. Markin, MD, PhD
Chair of the Board & Independent Director
Dr. Markin has been Chairman of the Board of our company since December 2020 and a Director since February 2014. Currently he is the Associate Vice President of Business Development for The University of Nebraska System since January 2026; Vice President of Business Development for Nebraska Medicine since October 2019; Associate Vice Chancellor for Business Development at University of Nebraska Medical Center; and Executive Director of UNeTech since 2016.
Additionally, he is also a Professor of Pathology and Microbiology since 1985; received the David T. Purtilo Distinguished Professor of Pathology and Microbiology in 2005; and is a courtesy Professor in the departments of Surgery (since 1993) and Psychiatry (since 1995).
Dr. Markin was previously a director on the Boards of UNMC Physicians and Nebraska Health Partners, and previously served as Chairman of the Board of Directors for Transgenomic, Inc. from March 2007 to December 2014.
Mark Erlander, PhD
Chief Executive Officer
Dr. Erlander has served as our Chief Executive Officer since May 2020 and formerly as the Chief Scientific Officer from March 2013 to May 2020.
Previously, he was Chief Scientific Officer at bioTheranostics, a subsidiary of bioMérieux, a molecular diagnostic testing company focused on clinical applications in oncology, where he served from 2008 to 2013. From 2000 to 2008, Dr. Erlander was Chief Scientific Officer at Arcturus, Inc. (later AviaraDx), which was acquired by bioMérieux in 2008. Dr. Erlander entered therapeutics as a Group Leader and then Research Fellow in drug discovery at Johnson & Johnson from 1994 to 2000. From 1991 to 1994, Dr. Erlander was a Postdoctoral Fellow and then Assistant Professor at Scripps Research. He has 44 issued patents, over 50 pending applications, and has co-authored more than 90 scientific publications.
Dr. Erlander holds a B.S. in Biochemistry from the University of California, Davis, an M.S. degree in Biochemistry from Iowa State University, and a Ph.D. in Neuroscience from the University of California, Los Angeles.
Lâle White
Independent Director
Ms. White has been a director of our company since April 2020. Ms. White is the Chief Executive Officer of XIFIN, Inc., a financial cloud computing company, with over 25 years of experience in information systems development and medical billing. She lectures extensively on these topics and has consulted for major laboratories and laboratory associations throughout the U.S. Ms. White worked with HCFA and the U.S. Office of the Inspector General to develop the first OIG Model Compliance Program.
She is a longstanding member of the California Clinical Lab Association, where for the last eight years she has chaired the state and federal contractor committees that work with the Medicare Administrative Contractors and the Department of Health and Human Services.
Ms. White was previously Vice President of Finance of Laboratory Corporation of America, one of the largest clinical reference laboratories in the U.S., and its predecessor National Health Laboratories, where she led the software development of several accounts receivable, inventory, cost accounting and financial management systems for the laboratory industry. Ms. White previously was on the Board of bioTheranostics while it was a BioMerieux subsidiary, and CombiMatrix Corporation, until its acquisition by Invitae Corporation in 2017. Ms. White has a BA in finance and an MBA from Florida International University.
Renee P. Tannenbaum, PharmD
Independent Director
Dr. Tannenbaum has been a director of our company since June 2021. Dr. Tannenbaum currently serves as a board director and an independent consultant and strategic advisor to several biopharmaceutical, diagnostic and device companies. From 2016 through 2021, she served in several roles at Halozyme Therapeutics, Inc., most recently as Vice President of Global Partnering, where she was responsible for leading the team that executes business development activities and the company’s alliances through partnerships and collaborations. Dr. Tannenbaum was previously Head of Global Customer Excellence at AbbVie from October 2012 to January 2016, where she was responsible for building commercial capabilities for the organization.
Previously, Dr. Tannenbaum served as President of Myrtle Potter & Company, LLC, a global life sciences consulting and advisory firm from April 2011 to October 2012, and as Executive Vice President and Chief Commercial Officer at Elan Pharmaceuticals, Inc., from May 2009 to January 2011, where she was responsible for revenue generation for Elan’s marketed products, preparing for the commercialization of the company’s pipeline, including its Alzheimer’s portfolio, and strengthening the company’s overall commercial capabilities. Prior to her role at Elan, Dr. Tannenbaum was at Novartis Pharma AG for three years, where she led the Global Commercial Operations organization. Prior to that, Dr. Tannenbaum spent nine years at Bristol Myers Squibb and 16 years at Merck and Company, Inc. where she held a variety of leadership positions in operations and general management.
Dr. Tannenbaum has served on the Board of Directors for ANI Pharmaceuticals, Inc. since March 2022. Dr. Tannenbaum has previously served as a director of Zogenix, Inc. from January 2015 to March 2022, Nordic Nanovector ASA, a publicly-traded company in Norway, and Cipher Pharmaceuticals, Inc., a Canadian publicly-traded company, from April to August 2016, Sharps Compliance Inc. from November 2012 to November 2014, and Immune Pharmaceuticals, Inc., a privately-held company, from August 2011 to October 2012. Dr. Tannenbaum received her Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Sciences, her MBA from Temple University, and her Bachelor of Science degree in Pharmacy from the University of Connecticut.
Rodney S. Markin, MD, PhD
Chair of the Board & Independent Director
Dr. Markin has been Chairman of the Board of our company since December 2020 and a Director since February 2014. Currently he is the Associate Vice President of Business Development for The University of Nebraska System since January 2026; Vice President of Business Development for Nebraska Medicine since October 2019; Associate Vice Chancellor for Business Development at University of Nebraska Medical Center; and Executive Director of UNeTech since 2016.
Additionally, he is also a Professor of Pathology and Microbiology since 1985; received the David T. Purtilo Distinguished Professor of Pathology and Microbiology in 2005; and is a courtesy Professor in the departments of Surgery (since 1993) and Psychiatry (since 1995).
Dr. Markin was previously a director on the Boards of UNMC Physicians and Nebraska Health Partners, and previously served as Chairman of the Board of Directors for Transgenomic, Inc. from March 2007 to December 2014.
Mark Erlander, PhD
Chief Executive Officer
Dr. Erlander has served as our Chief Executive Officer since May 2020 and formerly as the Chief Scientific Officer from March 2013 to May 2020.
Previously, he was Chief Scientific Officer at bioTheranostics, a subsidiary of bioMérieux, a molecular diagnostic testing company focused on clinical applications in oncology, where he served from 2008 to 2013. From 2000 to 2008, Dr. Erlander was Chief Scientific Officer at Arcturus, Inc. (later AviaraDx), which was acquired by bioMérieux in 2008. Dr. Erlander entered therapeutics as a Group Leader and then Research Fellow in drug discovery at Johnson & Johnson from 1994 to 2000. From 1991 to 1994, Dr. Erlander was a Postdoctoral Fellow and then Assistant Professor at Scripps Research. He has 44 issued patents, over 50 pending applications, and has co-authored more than 90 scientific publications.
Dr. Erlander holds a B.S. in Biochemistry from the University of California, Davis, an M.S. degree in Biochemistry from Iowa State University, and a Ph.D. in Neuroscience from the University of California, Los Angeles.
Lâle White
Independent Director
Ms. White has been a director of our company since April 2020. Ms. White is the Chief Executive Officer of XIFIN, Inc., a financial cloud computing company, with over 25 years of experience in information systems development and medical billing. She lectures extensively on these topics and has consulted for major laboratories and laboratory associations throughout the U.S. Ms. White worked with HCFA and the U.S. Office of the Inspector General to develop the first OIG Model Compliance Program.
She is a longstanding member of the California Clinical Lab Association, where for the last eight years she has chaired the state and federal contractor committees that work with the Medicare Administrative Contractors and the Department of Health and Human Services.
Ms. White was previously Vice President of Finance of Laboratory Corporation of America, one of the largest clinical reference laboratories in the U.S., and its predecessor National Health Laboratories, where she led the software development of several accounts receivable, inventory, cost accounting and financial management systems for the laboratory industry. Ms. White previously was on the Board of bioTheranostics while it was a BioMerieux subsidiary, and CombiMatrix Corporation, until its acquisition by Invitae Corporation in 2017. Ms. White has a BA in finance and an MBA from Florida International University.
Renee P. Tannenbaum, PharmD
Independent Director
Dr. Tannenbaum has been a director of our company since June 2021. Dr. Tannenbaum currently serves as a board director and an independent consultant and strategic advisor to several biopharmaceutical, diagnostic and device companies. From 2016 through 2021, she served in several roles at Halozyme Therapeutics, Inc., most recently as Vice President of Global Partnering, where she was responsible for leading the team that executes business development activities and the company’s alliances through partnerships and collaborations. Dr. Tannenbaum was previously Head of Global Customer Excellence at AbbVie from October 2012 to January 2016, where she was responsible for building commercial capabilities for the organization.
Previously, Dr. Tannenbaum served as President of Myrtle Potter & Company, LLC, a global life sciences consulting and advisory firm from April 2011 to October 2012, and as Executive Vice President and Chief Commercial Officer at Elan Pharmaceuticals, Inc., from May 2009 to January 2011, where she was responsible for revenue generation for Elan’s marketed products, preparing for the commercialization of the company’s pipeline, including its Alzheimer’s portfolio, and strengthening the company’s overall commercial capabilities. Prior to her role at Elan, Dr. Tannenbaum was at Novartis Pharma AG for three years, where she led the Global Commercial Operations organization. Prior to that, Dr. Tannenbaum spent nine years at Bristol Myers Squibb and 16 years at Merck and Company, Inc. where she held a variety of leadership positions in operations and general management.
Dr. Tannenbaum has served on the Board of Directors for ANI Pharmaceuticals, Inc. since March 2022. Dr. Tannenbaum has previously served as a director of Zogenix, Inc. from January 2015 to March 2022, Nordic Nanovector ASA, a publicly-traded company in Norway, and Cipher Pharmaceuticals, Inc., a Canadian publicly-traded company, from April to August 2016, Sharps Compliance Inc. from November 2012 to November 2014, and Immune Pharmaceuticals, Inc., a privately-held company, from August 2011 to October 2012. Dr. Tannenbaum received her Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Sciences, her MBA from Temple University, and her Bachelor of Science degree in Pharmacy from the University of Connecticut.
Mani Mohindru, PhD
Independent Director
Dr. Mohindru has served as our Interim Chief Executive Officer since January 2026, President and Chief Executive Officer since late March 2026 and has been a director since 2021. She is a co-founder and Board Chair of Roshon Therapeutics, Inc., an early-stage, private biotech company developing antibodies for the treatment of cancer and inflammatory diseases.
Previously, Dr. Mohindru was CEO and Board Director of Novasenta Inc., an oncology-focused biotech company. Dr. Mohindru previously worked in executive roles at several additional biotechnology companies, having served as Chief Executive Officer of CereXis, Inc., Chief Financial Officer and Chief Strategy Officer of Cara Therapeutics, Inc. (Nasdaq: CARA), and Chief Strategy Officer at Curis, Inc (Nasdaq: CRIS). Prior to her leadership roles in the biotechnology industry, Dr. Mohindru spent several years as an equity research analyst covering the biotechnology sector at UBS, Credit Suisse and ThinkEquity.
In addition to her position at Cardiff Oncology, Dr. Mohindru serves as a member of the Board of Directors at CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage biopharmaceutical company. She was previously a member of the Board of Directors of SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company. Dr. Mohindru received her Ph.D. in Neurosciences from Northwestern University and her master’s in biotechnology and B.S. in Human Biology (Hons) from the All India Institute of Medical Sciences.
James O. Armitage, MD
Independent Director
Dr. Armitage has been a director of our company since April 2020. Dr. Armitage has been a Professor of Internal Medicine in the division of Hematology and Oncology at the University of Nebraska Medical Center since 2003, after having served as Chairman of the Department of Internal Medicine, Dean of the College of Medicine, and in various other capacities since joining the Center in 1982. He also holds a hospital appointment at The Nebraska Medical Center.
Dr. Armitage has authored or co-authored more than 600 articles, 108 book chapters and edited or co-edited 27 textbooks. He has previously served as President of the American Society of Clinical Oncology (“ASCO”), and as a member of the ASCO Board of Directors.
Dr. Armitage received a bachelor of science degree from the University of Nebraska and a medical degree from the University of Nebraska Medical Center and completed his post-graduate training at the University of Nebraska Medical Center and the University of Iowa Hospitals and Clinics.
Gary W. Pace, PhD
Independent Director
Dr. Pace has been a director of our company since April 2020. In addition, Dr. Pace served as a Director of Pacira BioSciences, Inc. from 2008 to 2024, and Antisense Therapeutics from 2015 to 2022, as well as a director of several private companies. He previously served on the board of Simavita Ltd. from 2016 to 2021, ResMed Inc. from 1994 to 2018, Transition Therapeutics Inc. from 2002 to 2016 and QRxPharma Ltd. from 2001 to 2013.
Dr. Pace is a seasoned biopharmaceutical executive with over 40 years of experience in the industry. He has co-founded several early-stage life science companies, where he built products from the laboratory to commercialization. Dr. Pace has contributed to the development of the biotechnology industry through honorary university appointments and industry and government committees. In 2003, he was awarded a Centenary Medal by the Australian Government “for service to Australian society in research and development” and was recognized as the 2011 Director of the Year (corporate governance) by the San Diego Directors Forum. He is also a fellow of the Australian Academy of Technological Sciences and Engineering.
Dr. Pace holds a B.Sc. (Hons I) from the University of New South Wales and a Ph.D. from the Massachusetts Institute of Technology where he was a Fulbright Fellow and General Foods Scholar.
Rodney S. Markin, MD, PhD
Chair of the Board & Independent Director
Dr. Markin has been Chairman of the Board of our company since December 2020 and a Director since February 2014. Currently he is the Associate Vice President of Business Development for The University of Nebraska System since January 2026; Vice President of Business Development for Nebraska Medicine since October 2019; Associate Vice Chancellor for Business Development at University of Nebraska Medical Center; and Executive Director of UNeTech since 2016.
Additionally, he is also a Professor of Pathology and Microbiology since 1985; received the David T. Purtilo Distinguished Professor of Pathology and Microbiology in 2005; and is a courtesy Professor in the departments of Surgery (since 1993) and Psychiatry (since 1995).
Dr. Markin was previously a director on the Boards of UNMC Physicians and Nebraska Health Partners, and previously served as Chairman of the Board of Directors for Transgenomic, Inc. from March 2007 to December 2014.
Mark Erlander, PhD
Chief Executive Officer
Dr. Erlander has served as our Chief Executive Officer since May 2020 and formerly as the Chief Scientific Officer from March 2013 to May 2020.
Previously, he was Chief Scientific Officer at bioTheranostics, a subsidiary of bioMérieux, a molecular diagnostic testing company focused on clinical applications in oncology, where he served from 2008 to 2013. From 2000 to 2008, Dr. Erlander was Chief Scientific Officer at Arcturus, Inc. (later AviaraDx), which was acquired by bioMérieux in 2008. Dr. Erlander entered therapeutics as a Group Leader and then Research Fellow in drug discovery at Johnson & Johnson from 1994 to 2000. From 1991 to 1994, Dr. Erlander was a Postdoctoral Fellow and then Assistant Professor at Scripps Research. He has 44 issued patents, over 50 pending applications, and has co-authored more than 90 scientific publications.
Dr. Erlander holds a B.S. in Biochemistry from the University of California, Davis, an M.S. degree in Biochemistry from Iowa State University, and a Ph.D. in Neuroscience from the University of California, Los Angeles.
Lâle White
Independent Director
Ms. White has been a director of our company since April 2020. Ms. White is the Chief Executive Officer of XIFIN, Inc., a financial cloud computing company, with over 25 years of experience in information systems development and medical billing. She lectures extensively on these topics and has consulted for major laboratories and laboratory associations throughout the U.S. Ms. White worked with HCFA and the U.S. Office of the Inspector General to develop the first OIG Model Compliance Program.
She is a longstanding member of the California Clinical Lab Association, where for the last eight years she has chaired the state and federal contractor committees that work with the Medicare Administrative Contractors and the Department of Health and Human Services.
Ms. White was previously Vice President of Finance of Laboratory Corporation of America, one of the largest clinical reference laboratories in the U.S., and its predecessor National Health Laboratories, where she led the software development of several accounts receivable, inventory, cost accounting and financial management systems for the laboratory industry. Ms. White previously was on the Board of bioTheranostics while it was a BioMerieux subsidiary, and CombiMatrix Corporation, until its acquisition by Invitae Corporation in 2017. Ms. White has a BA in finance and an MBA from Florida International University.
Renee P. Tannenbaum, PharmD
Independent Director
Dr. Tannenbaum has been a director of our company since June 2021. Dr. Tannenbaum currently serves as a board director and an independent consultant and strategic advisor to several biopharmaceutical, diagnostic and device companies. From 2016 through 2021, she served in several roles at Halozyme Therapeutics, Inc., most recently as Vice President of Global Partnering, where she was responsible for leading the team that executes business development activities and the company’s alliances through partnerships and collaborations. Dr. Tannenbaum was previously Head of Global Customer Excellence at AbbVie from October 2012 to January 2016, where she was responsible for building commercial capabilities for the organization.
Previously, Dr. Tannenbaum served as President of Myrtle Potter & Company, LLC, a global life sciences consulting and advisory firm from April 2011 to October 2012, and as Executive Vice President and Chief Commercial Officer at Elan Pharmaceuticals, Inc., from May 2009 to January 2011, where she was responsible for revenue generation for Elan’s marketed products, preparing for the commercialization of the company’s pipeline, including its Alzheimer’s portfolio, and strengthening the company’s overall commercial capabilities. Prior to her role at Elan, Dr. Tannenbaum was at Novartis Pharma AG for three years, where she led the Global Commercial Operations organization. Prior to that, Dr. Tannenbaum spent nine years at Bristol Myers Squibb and 16 years at Merck and Company, Inc. where she held a variety of leadership positions in operations and general management.
Dr. Tannenbaum has served on the Board of Directors for ANI Pharmaceuticals, Inc. since March 2022. Dr. Tannenbaum has previously served as a director of Zogenix, Inc. from January 2015 to March 2022, Nordic Nanovector ASA, a publicly-traded company in Norway, and Cipher Pharmaceuticals, Inc., a Canadian publicly-traded company, from April to August 2016, Sharps Compliance Inc. from November 2012 to November 2014, and Immune Pharmaceuticals, Inc., a privately-held company, from August 2011 to October 2012. Dr. Tannenbaum received her Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Sciences, her MBA from Temple University, and her Bachelor of Science degree in Pharmacy from the University of Connecticut.
Mani Mohindru, PhD
Independent Director
Dr. Mohindru has served as our Interim Chief Executive Officer since January 2026, President and Chief Executive Officer since late March 2026 and has been a director since 2021. She is a co-founder and Board Chair of Roshon Therapeutics, Inc., an early-stage, private biotech company developing antibodies for the treatment of cancer and inflammatory diseases.
Previously, Dr. Mohindru was CEO and Board Director of Novasenta Inc., an oncology-focused biotech company. Dr. Mohindru previously worked in executive roles at several additional biotechnology companies, having served as Chief Executive Officer of CereXis, Inc., Chief Financial Officer and Chief Strategy Officer of Cara Therapeutics, Inc. (Nasdaq: CARA), and Chief Strategy Officer at Curis, Inc (Nasdaq: CRIS). Prior to her leadership roles in the biotechnology industry, Dr. Mohindru spent several years as an equity research analyst covering the biotechnology sector at UBS, Credit Suisse and ThinkEquity.
In addition to her position at Cardiff Oncology, Dr. Mohindru serves as a member of the Board of Directors at CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage biopharmaceutical company. She was previously a member of the Board of Directors of SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company. Dr. Mohindru received her Ph.D. in Neurosciences from Northwestern University and her master’s in biotechnology and B.S. in Human Biology (Hons) from the All India Institute of Medical Sciences.
James O. Armitage, MD
Independent Director
Dr. Armitage has been a director of our company since April 2020. Dr. Armitage has been a Professor of Internal Medicine in the division of Hematology and Oncology at the University of Nebraska Medical Center since 2003, after having served as Chairman of the Department of Internal Medicine, Dean of the College of Medicine, and in various other capacities since joining the Center in 1982. He also holds a hospital appointment at The Nebraska Medical Center.
Dr. Armitage has authored or co-authored more than 600 articles, 108 book chapters and edited or co-edited 27 textbooks. He has previously served as President of the American Society of Clinical Oncology (“ASCO”), and as a member of the ASCO Board of Directors.
Dr. Armitage received a bachelor of science degree from the University of Nebraska and a medical degree from the University of Nebraska Medical Center and completed his post-graduate training at the University of Nebraska Medical Center and the University of Iowa Hospitals and Clinics.
Gary W. Pace, PhD
Independent Director
Dr. Pace has been a director of our company since April 2020. In addition, Dr. Pace served as a Director of Pacira BioSciences, Inc. from 2008 to 2024, and Antisense Therapeutics from 2015 to 2022, as well as a director of several private companies. He previously served on the board of Simavita Ltd. from 2016 to 2021, ResMed Inc. from 1994 to 2018, Transition Therapeutics Inc. from 2002 to 2016 and QRxPharma Ltd. from 2001 to 2013.
Dr. Pace is a seasoned biopharmaceutical executive with over 40 years of experience in the industry. He has co-founded several early-stage life science companies, where he built products from the laboratory to commercialization. Dr. Pace has contributed to the development of the biotechnology industry through honorary university appointments and industry and government committees. In 2003, he was awarded a Centenary Medal by the Australian Government “for service to Australian society in research and development” and was recognized as the 2011 Director of the Year (corporate governance) by the San Diego Directors Forum. He is also a fellow of the Australian Academy of Technological Sciences and Engineering.
Dr. Pace holds a B.Sc. (Hons I) from the University of New South Wales and a Ph.D. from the Massachusetts Institute of Technology where he was a Fulbright Fellow and General Foods Scholar.
Rodney S. Markin, MD, PhD
Chair of the Board & Independent Director
Dr. Markin has been Chairman of the Board of our company since December 2020 and a Director since February 2014. Currently he is the Associate Vice President of Business Development for The University of Nebraska System since January 2026; Vice President of Business Development for Nebraska Medicine since October 2019; Associate Vice Chancellor for Business Development at University of Nebraska Medical Center; and Executive Director of UNeTech since 2016.
Additionally, he is also a Professor of Pathology and Microbiology since 1985; received the David T. Purtilo Distinguished Professor of Pathology and Microbiology in 2005; and is a courtesy Professor in the departments of Surgery (since 1993) and Psychiatry (since 1995).
Dr. Markin was previously a director on the Boards of UNMC Physicians and Nebraska Health Partners, and previously served as Chairman of the Board of Directors for Transgenomic, Inc. from March 2007 to December 2014.
Mani Mohindru, PhD
President & Chief Executive Officer
Dr. Mohindru has served as our Interim Chief Executive Officer since January 2026, President and Chief Executive Officer since late March 2026 and has been a director since 2021. She is a co-founder and Board Chair of Roshon Therapeutics, Inc., an early-stage, private biotech company developing antibodies for the treatment of cancer and inflammatory diseases.
Previously, Dr. Mohindru was CEO and Board Director of Novasenta Inc., an oncology-focused biotech company. Dr. Mohindru previously worked in executive roles at several additional biotechnology companies, having served as Chief Executive Officer of CereXis, Inc., Chief Financial Officer and Chief Strategy Officer of Cara Therapeutics, Inc. (Nasdaq: CARA), and Chief Strategy Officer at Curis, Inc (Nasdaq: CRIS). Prior to her leadership roles in the biotechnology industry, Dr. Mohindru spent several years as an equity research analyst covering the biotechnology sector at UBS, Credit Suisse and ThinkEquity.
In addition to her position at Cardiff Oncology, Dr. Mohindru serves as a member of the Board of Directors at CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage biopharmaceutical company. She was previously a member of the Board of Directors of SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company. Dr. Mohindru received her Ph.D. in Neurosciences from Northwestern University and her master’s in biotechnology and B.S. in Human Biology (Hons) from the All India Institute of Medical Sciences.
James O. Armitage, MD
Independent Director
Dr. Armitage has been a director of our company since April 2020. Dr. Armitage has been a Professor of Internal Medicine in the division of Hematology and Oncology at the University of Nebraska Medical Center since 2003, after having served as Chairman of the Department of Internal Medicine, Dean of the College of Medicine, and in various other capacities since joining the Center in 1982. He also holds a hospital appointment at The Nebraska Medical Center.
Dr. Armitage has authored or co-authored more than 600 articles, 108 book chapters and edited or co-edited 27 textbooks. He has previously served as President of the American Society of Clinical Oncology (“ASCO”), and as a member of the ASCO Board of Directors.
Dr. Armitage received a bachelor of science degree from the University of Nebraska and a medical degree from the University of Nebraska Medical Center and completed his post-graduate training at the University of Nebraska Medical Center and the University of Iowa Hospitals and Clinics.
Gary W. Pace, PhD
Independent Director
Dr. Pace has been a director of our company since April 2020. In addition, Dr. Pace served as a Director of Pacira BioSciences, Inc. from 2008 to 2024, and Antisense Therapeutics from 2015 to 2022, as well as a director of several private companies. He previously served on the board of Simavita Ltd. from 2016 to 2021, ResMed Inc. from 1994 to 2018, Transition Therapeutics Inc. from 2002 to 2016 and QRxPharma Ltd. from 2001 to 2013.
Dr. Pace is a seasoned biopharmaceutical executive with over 40 years of experience in the industry. He has co-founded several early-stage life science companies, where he built products from the laboratory to commercialization. Dr. Pace has contributed to the development of the biotechnology industry through honorary university appointments and industry and government committees. In 2003, he was awarded a Centenary Medal by the Australian Government “for service to Australian society in research and development” and was recognized as the 2011 Director of the Year (corporate governance) by the San Diego Directors Forum. He is also a fellow of the Australian Academy of Technological Sciences and Engineering.
Dr. Pace holds a B.Sc. (Hons I) from the University of New South Wales and a Ph.D. from the Massachusetts Institute of Technology where he was a Fulbright Fellow and General Foods Scholar.
Renee P. Tannenbaum, PharmD
Independent Director
Dr. Tannenbaum has been a director of our company since June 2021. Dr. Tannenbaum currently serves as a board director and an independent consultant and strategic advisor to several biopharmaceutical, diagnostic and device companies. From 2016 through 2021, she served in several roles at Halozyme Therapeutics, Inc., most recently as Vice President of Global Partnering, where she was responsible for leading the team that executes business development activities and the company’s alliances through partnerships and collaborations. Dr. Tannenbaum was previously Head of Global Customer Excellence at AbbVie from October 2012 to January 2016, where she was responsible for building commercial capabilities for the organization.
Previously, Dr. Tannenbaum served as President of Myrtle Potter & Company, LLC, a global life sciences consulting and advisory firm from April 2011 to October 2012, and as Executive Vice President and Chief Commercial Officer at Elan Pharmaceuticals, Inc., from May 2009 to January 2011, where she was responsible for revenue generation for Elan’s marketed products, preparing for the commercialization of the company’s pipeline, including its Alzheimer’s portfolio, and strengthening the company’s overall commercial capabilities. Prior to her role at Elan, Dr. Tannenbaum was at Novartis Pharma AG for three years, where she led the Global Commercial Operations organization. Prior to that, Dr. Tannenbaum spent nine years at Bristol Myers Squibb and 16 years at Merck and Company, Inc. where she held a variety of leadership positions in operations and general management.
Dr. Tannenbaum has served on the Board of Directors for ANI Pharmaceuticals, Inc. since March 2022. Dr. Tannenbaum has previously served as a director of Zogenix, Inc. from January 2015 to March 2022, Nordic Nanovector ASA, a publicly-traded company in Norway, and Cipher Pharmaceuticals, Inc., a Canadian publicly-traded company, from April to August 2016, Sharps Compliance Inc. from November 2012 to November 2014, and Immune Pharmaceuticals, Inc., a privately-held company, from August 2011 to October 2012. Dr. Tannenbaum received her Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Sciences, her MBA from Temple University, and her Bachelor of Science degree in Pharmacy from the University of Connecticut.
Lâle White
Independent Director
Ms. White has been a director of our company since April 2020. Ms. White is the Chief Executive Officer of XIFIN, Inc., a financial cloud computing company, with over 25 years of experience in information systems development and medical billing. She lectures extensively on these topics and has consulted for major laboratories and laboratory associations throughout the U.S. Ms. White worked with HCFA and the U.S. Office of the Inspector General to develop the first OIG Model Compliance Program.
She is a longstanding member of the California Clinical Lab Association, where for the last eight years she has chaired the state and federal contractor committees that work with the Medicare Administrative Contractors and the Department of Health and Human Services.
Ms. White was previously Vice President of Finance of Laboratory Corporation of America, one of the largest clinical reference laboratories in the U.S., and its predecessor National Health Laboratories, where she led the software development of several accounts receivable, inventory, cost accounting and financial management systems for the laboratory industry. Ms. White previously was on the Board of bioTheranostics while it was a BioMerieux subsidiary, and CombiMatrix Corporation, until its acquisition by Invitae Corporation in 2017. Ms. White has a BA in finance and an MBA from Florida International University.